| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 431.3 | 287.3 |
| Net income | 55.4 | -114.2 |
| EPS (diluted, $ a share) | $1.83 | $-4.01 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +50.1% |
|---|---|
| Operating margin | 13.0% |
10-Q filed with the SEC, NASDAQ: MDGL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Madrigal Pharmaceuticals, Inc.: key numbers
- Share price
- $423.96Close, Nov 16
- Market cap
- $9.85B
- Shares outstanding
- 23.23MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Madrigal Pharmaceuticals, Inc.
All →Madrigal Pharmaceuticals Director Baker Bros. Advisors LP Buys $35M of Stock
Baker Bros. Advisors LP, Director, bought 91,806 shares of Madrigal Pharmaceuticals, Inc. at $366.99 to $396.61 a share (average $381.49) in 5 transactions, worth $35M in total between Nov 4, 2026 and Nov 6, 2026. Shares held after the trade: 2,040,682 (+0.1%).
- Value
- $35M
- Shares
- 91,806
- Average price
- $381.49
- Role
- Director
- Holding change
- +0.1%
- Trade date
- Nov 4, 2026 to Nov 6, 2026
Madrigal Pharmaceuticals General Counsel Shannon T. Kelley Sells $431K of Stock
Shannon T. Kelley, General Counsel, sold 1,077 shares of Madrigal Pharmaceuticals, Inc. at $400.00 a share, worth $431K in total on Nov 6, 2026. Shares held after the trade: 10,397 (-9.4%).
- Value
- $431K
- Shares
- 1,077
- Price
- $400.00
- Role
- General Counsel
- Holding change
- -9.4%
- Trade date
- Nov 6, 2026
Madrigal Pharmaceuticals Financial Results
Madrigal Pharmaceuticals reported third-quarter 2026 financial results, highlighted by Rezdiffra net sales of $431.3 million and the achievement of its first quarter of profitability. The company also announced that Rezdiffra reached blockbuster status with year-to-date net sales of $1.1 billion and plans to initiate a new Phase 3 outcomes trial, MAESTRO-CSPH, in the first half of 2027.
“Madrigal delivered another strong quarter, driven by continued Rezdiffra demand, deepening prescriber adoption and accelerating market growth. Rezdiffra surpassed $1 billion in year-to-date net sales, achieving blockbuster status less than three years after launch, and we are still early in a rapidly growing market.”
Bill Sibold, Chief Executive Officer of Madrigal
“Madrigal’s next major opportunity is in well-compensated cirrhosis, or F4c, an urgent unmet need for patients. Our objective in F4c is clear: be first and best. Our ongoing MAESTRO-NASH OUTCOMES trial positions us to deliver the first approved therapy to patients with this advanced stage of MASH.”
Bill Sibold, Chief Executive Officer of Madrigal